Cantor Fitzgerald analyst Steven Halper reiterated a Hold rating on Teladoc (TDOC) yesterday and set a price target of $83. The company’s shares closed on Tuesday at $59.81.
Halper observed:
“We characterize our estimates in our long-term DCF model as aggressive. We continue to believe the current share valuation already reflects the long-term growth opportunity. $83 DCF price target is based on continued high rates of revenue growth, improving operating margins, positive free cash flow beginning in 2018 and a 8.5% discount rate assumption. The Disclosure Section may be found on pages 3 – 4.Valuation Our DCF-based price target for TDOC shares is $83 in 12 months.”
According to TipRanks.com, Halper is a top 25 analyst with an average return of 20.9% and a 69.7% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Hms Holdings Corp.
Currently, the analyst consensus on Teladoc is a Strong Buy with an average price target of $91.54.
See today’s analyst top recommended stocks >>
Based on Teladoc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $23.26 million. In comparison, last year the company had a GAAP net loss of $31.33 million.
Based on the recent corporate insider activity of 58 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of TDOC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. Its portfolio of services and solutions covers medical subspecialties from non-urgent, episodic needs like flu and upper respiratory infections, to chronic, complicated medical conditions like cancer and congestive heart failure. The company was founded on June 13, 2002 by George Byron Brooks and is headquartered in Purchase, NY.
